Pfizer (PFE)

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls.

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market attention.

Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today.

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Investing in high-quality stocks with generous dividend payouts can help you gradually build substantial wealth.

Income investors can capture yields above 5% from companies executing business transformations.

On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P 500 Healthcare Sector closed the day without any explicit, significant sector-wide news driving its performance. Instead, its movements largely mirrored the

Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE) and Dow (DOW) discussed. Plug Power (PLUG) faces concerns over shareholder dilution.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations. 

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for pregnant women.

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a

Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

This pharma giant is entering the rapidly expanding market for weight loss drugs.

The pharma giant is slated to report its latest quarterly numbers next week.

The Dow Jones Industrial Average (DJIA) recently achieved a significant milestone, surging by over 200 points to close at an unprecedented all-time record high in October 2025. This remarkable ascent is a powerful testament to renewed market confidence and a confluence of positive economic indicators, sending a clear signal of

These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again.

Vertex appears to be by far the better buy right now.

If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.